Figure 3.

Phagocytosis of dying Jurkat cell. (a) Jurkat cells were labeled with CFSE and cultured in UC medium in the presence of 20 μM oxaliplatin for 48 h. Then cells were incubated for an additional hour in UC medium either without supplementation or supplemented with purified C1q, or C1q-depleted serum, or C1q-depleted serum with 20 μg/ml purified C1q. Then cells were mixed with CD14⁺ primary human monocytes from four different volunteers (HV01–HV04) and incubated for an additional 2 h for phagocytosis in serum-free UC medium. (b) Jurkat cells were treated the same way as in a, then mixed with CD14⁺ monocyte-derived macrophages from four different volunteers (HV01–HV04) and incubated for an additional 2 h for phagocytosis in serum-free UC medium. (c) Jurkat cells were treated with oxaliplatin as described above, incubated for 1 h in UC medium supplemented with 25% NHS and then sorted according to the FS/7AAD graph in populations I, II and III. Then the subpopulations were mixed with CD14⁺ primary human monocytes from four different donors (HV01–HV04) and incubated for an additional 2 h for phagocytosis. Untreated cells were used as negative control. The phagocytosis index indicates the percentage of CFSE⁺ monocytes/macrophages as assessed by flow cytometry